Non-Small-Cell Lung Cancer | Current Treatment: Physician Insights | US | 2018
The treatment landscape for NSCLC continues to evolve at a rapid pace with the additions of new therapies and label expansions of current therapies into new patient populations. Examples include the approvals of Alunbrig for ALK-positive metastatic NSCLC,Tafinlar plus Mekinist for BRAF-mutation-positive NSCLC, and Imfinzi for unresectable stage III NSCLC as well as the label expansion of Keytruda in combination with chemotherapy as a first-line regimen for metastatic nonsquamous patients. Our primary research provides insight into the current use of approved therapies for NSCLC in the United States and uncovers key factors that influence medical oncologists’ prescribing decisions in this highly dynamic indication.
Related Market Assessment Reports
Report
Systemic Lupus Erythematosus | Unmet Need | Moderate to Severe Systemic Lupus Erythematosus | US/EU | 2024
Systemic lupus erythematosus (SLE) is an autoimmune disease that can affect different organ systems of the body and manifest in a wide range of clinical symptoms, from general fatigue to serious…
Report
Systemic Lupus Erythematosus – Unmet Need – Unmet Need – Moderate to Severe Systemic Lupus Erythematosus (US/EU)
Systemic lupus erythematosus (SLE) is an autoimmune disease that can affect different organ systems of the body and manifest in a wide range of clinical symptoms, from general fatigue to serious…
Report
Immune Thrombocytopenic Purpura – Unmet Need – Unmet Need – Immune Thrombocytopenic Purpura (US/EU)
Immune thrombocytopenic purpura (ITP) is an autoimmune disorder marked by increased platelet destruction and impaired megakaryocyte production. Bleeding ranges from petechiae to lifethreatening…
